<DOC>
	<DOCNO>NCT00272480</DOCNO>
	<brief_summary>To determine whether use two antiviral agent combination well placebo treatment inflammatory sidease spinal cord cause HTLV-I</brief_summary>
	<brief_title>Zidovudine Plus Lamivudine HTLV-I-associated Myelopathy : Randomised Trial</brief_title>
	<detailed_description>Randomised , double-blind , placebo-controlled two centre study zidvoudine plus lamivudine HAM/TSP 24 patient randomise 1:1 2-4 week lead-in 6 month randomise phase follow 6 month open-label therapy active drug Primary endpoint : clinical Secondary endpoint : virological immunological</detailed_description>
	<mesh_term>Spinal Cord Diseases</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Paraparesis , Tropical Spastic</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HTLVIassociated myelopathy prior exposure zidovudine lamvudine disease modify therapy age 16</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>HAM/TSP</keyword>
	<keyword>HTLV-I-associated myelopathy</keyword>
	<keyword>zidovudine</keyword>
	<keyword>lamivudine</keyword>
	<keyword>antiretroviral therapy</keyword>
</DOC>